Recurrent Childhood Medulloblastoma Clinical Trial
Official title:
Phase I Study of Intraventricular Infusions of Autologous Ex Vivo-Expanded NK Cells in Children With Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System. NOAH's (New Opportunity, Advancing Hope) Protocol
Verified date | August 2020 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase I trial studies the side effects and best dose of expanded natural killer cells in treating younger patients with brain tumors that have come back or do not respond to treatment. Infusing a particular type of a patient's own white blood cells called natural killer cells that have been through a procedure to expand (increase) their numbers may work in treating patients with recurrent/refractory brain tumors.
Status | Completed |
Enrollment | 12 |
Est. completion date | August 28, 2020 |
Est. primary completion date | August 28, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 21 Years |
Eligibility |
Inclusion Criteria: - Diagnosis: patients with recurrent/refractory medulloblastoma (MB), atypical teratoid (AT)/rhabdoid tumors (RT) or ependymoma involving the brain and/or spine at original diagnosis or relapse; they must have histological verification at diagnosis and/or relapse; patient must have presented with these tumors in the posterior fossa (PF) or relapsed in the PF - Patient must have either measurable or evaluable tumor - Presence of or determined by neurosurgery to be a candidate for an implanted catheter in the ventricles to receive NK cell infusion - Life expectancy of at least 12 weeks in opinion of principal investigator (PI) and/or designee - Lansky score of 50 or greater if =<16 years of age or a Karnofsky score of 50 or greater if > 16 years of age (NOTE: patients who are unable to walk because of paralysis, but who are in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score) - Neurologic deficits must have been relatively stable for a minimum of 1 week prior to study enrollment - Patients must have recovered from the acute toxic effects of all prior anticancer chemotherapy - Patient must be 4 weeks off any palliative radiation or craniospinal radiation - Absolute neutrophil count (ANC) of >= 1000/uL - Platelet count of >= 30,000 - Hemoglobin of >= 9.0 g/dl - Patients with a seizure disorder may be enrolled if well-controlled and on non-enzyme inducing anticonvulsants - Patient or patient's legal representative, parent(s), or guardian able to provide written informed consent Exclusion Criteria: - Enrolled in another treatment protocol - Evidence of untreated infection - Extra-cranial metastasis - Chronic corticosteroid dependence (except replacement therapy) - Extensive disease, disease location, and/or co-morbid condition that the PI or designee considers unsafe for surgical intervention of NK cell infusion - Pregnant or lactating women |
Country | Name | City | State |
---|---|---|---|
United States | M D Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose (MTD) of natural killer (NK) cells | Defined as the highest dose studied in which 6 patients have been treated at most 1 patient with dose limiting toxicities are observed. Toxicities will be summarized by tabulation in terms of type, grade and attribution for each dose level of each group of patients studied at the end of the trial. | 4 weeks | |
Secondary | Activation status of NK cells | Determined by flow-based activation assay determining cluster of differentiation (CD)107a expression of NK cells in response to standardized targets. | Up to 30 days after the last infusion in course 3 | |
Secondary | Persistence of NK cells | Peripheral blood and cerebrospinal fluid (CSF) will be obtained before therapy, during the NK cell treatment period, and after NK cell treatment. | Up to 30 days after the last infusion in course 3 | |
Secondary | Function of NK cells | Assessed by cell lysis of standardized targets. | Up to 30 days after the last infusion in course 3 | |
Secondary | Response of medulloblastoma to NK cells | Antitumor activity will be described for each group of patients based on imaging and cytology. Clinical response will be correlated with NK cell persistence in vivo, cytokine levels, and expression of activation markers. | Up to 30 days after the last infusion in course 3 | |
Secondary | Feasibility of NK cell manufacturing | If analysis shows < 50% successful product generation after at least six patients have been enrolled, the study will be temporarily stopped to address possible changes in the manufacturing process. | Up to 12 weeks | |
Secondary | Feasibility of delivering NK cells | Therapy will be considered feasible if at least 2/3 of subjects treated receive at least 21 of the planned 27 NK cell infusions. | Up to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02194452 -
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
|
N/A | |
Completed |
NCT00053963 -
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
|
Phase 1 | |
Completed |
NCT00095940 -
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00052780 -
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
|
Phase 1 | |
Completed |
NCT00004078 -
Irinotecan in Treating Children With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT01239316 -
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
|
Phase 2 | |
Completed |
NCT00100880 -
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
|
Phase 1 | |
Completed |
NCT00070525 -
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
|
Phase 2 | |
Terminated |
NCT01088763 -
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
|
Phase 1 | |
Completed |
NCT00326664 -
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
|
Phase 1 | |
Completed |
NCT00101270 -
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT03210714 -
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Completed |
NCT02444546 -
Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
|
Phase 1 | |
Completed |
NCT00363272 -
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
|
Phase 1 | |
Completed |
NCT00946335 -
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
|
Phase 1 | |
Completed |
NCT00063973 -
Cilengitide in Treating Children With Refractory Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00822458 -
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
|
Phase 1 | |
Active, not recruiting |
NCT00638898 -
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
|
Phase 1 | |
Terminated |
NCT02684071 -
Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
|
Phase 2 | |
Completed |
NCT01076530 -
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
|
Phase 1 |